These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 16254479)

  • 1. Design issues and outcomes in IBD clinical trials.
    Sands BE; Abreu MT; Ferry GD; Griffiths AM; Hanauer SB; Isaacs KL; Lewis JD; Sandborn WJ; Steinhart AH
    Inflamm Bowel Dis; 2005 Nov; 11 Suppl 1():S22-8. PubMed ID: 16254479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current issues in the design of clinical trials in IBD.
    Feagan BG
    Nestle Nutr Inst Workshop Ser; 2014; 79():19-28. PubMed ID: 25227292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Converging goals of treatment of inflammatory bowel disease from clinical trials and practice.
    Levesque BG; Sandborn WJ; Ruel J; Feagan BG; Sands BE; Colombel JF
    Gastroenterology; 2015 Jan; 148(1):37-51.e1. PubMed ID: 25127678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methodological problems in RCTs on IBD.
    Cottone M; Criscuoli V; Modesto I; Orlando A
    Rev Recent Clin Trials; 2012 Nov; 7(4):284-9. PubMed ID: 23092230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers and surrogate endpoints in clinical trials.
    Fleming TR; Powers JH
    Stat Med; 2012 Nov; 31(25):2973-84. PubMed ID: 22711298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey.
    Ma C; Panaccione R; Fedorak RN; Parker CE; Khanna R; Levesque BG; Sandborn WJ; Feagan BG; Jairath V
    BMJ Open; 2017 Jun; 7(6):e016146. PubMed ID: 28601837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steps toward harmonization for clinical development of medicines in pediatric ulcerative colitis-a global scientific discussion, part 1: efficacy endpoints and disease outcome assessments.
    Sun H; Vesely R; Taminiau J; Szitanyi P; Papadopoulos EJ; Isaac M; Klein A; Uzu S; Griebel D; Mulberg AE;
    J Pediatr Gastroenterol Nutr; 2014 Jun; 58(6):679-83. PubMed ID: 24866781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial.
    Heida A; Dijkstra A; Groen H; Muller Kobold A; Verkade H; van Rheenen P
    Trials; 2015 Jun; 16():271. PubMed ID: 26073770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes and endpoints in trials of cancer treatment: the past, present, and future.
    Wilson MK; Karakasis K; Oza AM
    Lancet Oncol; 2015 Jan; 16(1):e32-42. PubMed ID: 25638553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of placebo therapy in inflammatory bowel disease.
    Su C
    Inflamm Bowel Dis; 2006 Apr; 12(4):328-33. PubMed ID: 16633054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two Decades of Cardiovascular Trials With Primary Surrogate Endpoints: 1990-2011.
    Bikdeli B; Punnanithinont N; Akram Y; Lee I; Desai NR; Ross JS; Krumholz HM
    J Am Heart Assoc; 2017 Mar; 6(3):. PubMed ID: 28325713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endpoints in cancer clinical trials.
    Fiteni F; Westeel V; Pivot X; Borg C; Vernerey D; Bonnetain F
    J Visc Surg; 2014 Feb; 151(1):17-22. PubMed ID: 24440056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standardisation of Study Protocols - Pros and Cons.
    D'Haens G
    J Crohns Colitis; 2016 Sep; 10 Suppl 2():S553-9. PubMed ID: 27604980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evolving Therapeutic Strategies in the Inflammatory Bowel Disease].
    Na SY; Moon W
    Korean J Gastroenterol; 2018 Feb; 71(2):61-68. PubMed ID: 29471602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Useful pharmacodynamic endpoints in children: selection, measurement, and next steps.
    Kelly LE; Sinha Y; Barker CIS; Standing JF; Offringa M
    Pediatr Res; 2018 Jun; 83(6):1095-1103. PubMed ID: 29667952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of psychological therapy on disease activity, psychological comorbidity, and quality of life in inflammatory bowel disease: a systematic review and meta-analysis.
    Gracie DJ; Irvine AJ; Sood R; Mikocka-Walus A; Hamlin PJ; Ford AC
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):189-199. PubMed ID: 28404134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient Reported Outcome Measures (PROMs) in Inflammatory Bowel Disease: New Data.
    Bojic D; Bodger K; Travis S
    J Crohns Colitis; 2017 Mar; 11(suppl_2):S576-S585. PubMed ID: 27797917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Placebo in Pediatric Inflammatory Bowel Diseases: A Position Paper From ESPGHAN, ECCO, PIBDnet, and the Canadian Children IBD Network.
    Turner D; Koletzko S; Griffiths AM; Hyams J; Dubinsky M; de Ridder L; Escher J; Lionetti P; Cucchiara S; Lentze MJ; Koletzko B; van Rheenen P; Russell RK; Mack D; Veereman G; Vermeire S; Ruemmele F
    J Pediatr Gastroenterol Nutr; 2016 Jan; 62(1):183-7. PubMed ID: 26545204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases.
    Lonn E
    Pharmacoepidemiol Drug Saf; 2001; 10(6):497-508. PubMed ID: 11828831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.